GLP1R and type 2 diabetes mellitus: Additionally, GLP1 receptor agonists have been shown to decrease cardiovascular risk in patients with type 2 diabetes, decrease hepatic steatosis, and improve inflammation in patients with noncirrhotic MAFLD [178].